BIOMAT Database Logo BIOMAT Database Logo

[Etofibrate in severe diet-refractory cases of hyperlipoproteinemia]. 1986

W Schatton, and E Holm

UI MeSH Term Description Entries
D006951 Hyperlipoproteinemias Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation. Hyperlipoproteinemia
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D002994 Clofibrate A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) Athromidin,Atromid,Atromid S,Clofibric Acid, Ethyl Ester,Ethyl Chlorophenoxyisobutyrate,Miscleron,Miskleron,Chlorophenoxyisobutyrate, Ethyl
D002995 Clofibric Acid An antilipemic agent that is the biologically active metabolite of CLOFIBRATE. Clofibrinic Acid,2-(4-Chlorophenoxy)-2-methylpropionic Acid,NSC-1149,p-Chlorophenoxyisobutyrate,p-Chlorophenoxyisobutyric Acid,NSC 1149,NSC1149
D004041 Dietary Fats Fats present in food, especially in animal products such as meat, meat products, butter, ghee. They are present in lower amounts in nuts, seeds, and avocados. Fats, Dietary,Dietary Fat,Fat, Dietary
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

W Schatton, and E Holm
[Long-term treatment of hyperlipoproteinemia with etofibrate].
September 1993, Fortschritte der Medizin,
W Schatton, and E Holm
Treatment of hyperlipoproteinemia type II with etofibrate.
December 1979, International journal of clinical pharmacology and biopharmacy,
W Schatton, and E Holm
[Comparative research on etofibrate retard and fenofibrate in hyperlipoproteinemia].
December 1980, Die Medizinische Welt,
W Schatton, and E Holm
Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
January 1980, Artery,
W Schatton, and E Holm
[Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard].
April 1980, Die Medizinische Welt,
W Schatton, and E Holm
[Diet therapy in hyperlipoproteinemia].
June 1975, Nederlands tijdschrift voor geneeskunde,
W Schatton, and E Holm
[Diet therapy of hyperlipoproteinemia].
January 1972, Professioni infermieristiche,
W Schatton, and E Holm
[What is important in therapy of hyperlipoproteinemia. Lipo-Merz retard (etofibrate) lowers the atherogenic index].
September 1982, Fortschritte der Medizin,
W Schatton, and E Holm
[Diet therapy in primary hyperlipoproteinemia].
February 1976, Polski tygodnik lekarski (Warsaw, Poland : 1960),
W Schatton, and E Holm
Influence of Etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia.
January 1976, Atherosclerosis,
Copied contents to your clipboard!